According to Alnylam’s Tim Mooney, mivelsiran’s endurance is due to stabilizing tweaks the scientists made to the siRNA ...

Yes, blood tests for Alzheimer’s disease are ready for prime time. So pronounced Suzanne Schindler, Washington University, St. Louis, in a keynote presentation at CTAD 2024 last month in Madrid. In ...

Rosa-Grilo incorporated Wave-CAIPI into the diagnostic scanning protocol used at UCL’s memory clinic. It comprises four sequences: T1-weighted 3D, T2-weighted 2D, T2-weighted 3D, and 3D FLAIR imaging.

Despite higher rates of clinically diagnosed dementia among people from non-white racial and ethnic groups, historically they have been underrepresented in AD clinical trials. Efforts are underway to ...

To keep patients on amyloid immunotherapy safe, doctors need to be able to spot subtle signs of ARIA on MRI scans. For memory clinics that have limited experience with these therapies, this may prove ...

Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation ...

An estimated 4,500 prescriptions have been filled in 2024 so far, Iwatsubo said. About 80 percent of patients have mild cognitive impairment, the rest have mild dementia. Most are in their 70s, and ...

Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...

Most discontinued anti-tau antibodies (red) targeted tau’s N-terminus. Of the antibodies currently in trials (green), bepranemab and E2814 presented results at CTAD, while JJ-63733657/posdinemab and ...